



Novel Technology and Vaccines Development for COVID-19

Guest Editors:

Dr. Chang Li

Dr. Penghua Wang

Prof. Dr. Bin Zhou

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

The continuous mutation of SARS-COV-2 is challenging the efficacy of applied vaccines. Therefore, it is urgently necessary to develop convenient, self-usable diagnostics or prevention tools based on mucosal technology in order to reduce side effects and increase accessibility. The fight against COVID-19 continues; therefore, it is crucial that we make progress regarding the development, improvement and effectiveness of COVID-19 vaccines.

Research areas may include (but not limited to) the following:

1. The progress in the designs, evaluations, and clinical trials in novel vaccines against SARS-CoV-2;
2. The development of universal vaccines to overcome SARS-CoV-2 variation;
3. The principles of escape neutralization caused by variation;
4. The models applied to evaluate vaccines in vitro or in vivo;
5. The novel tools for COVID-19 prevention and control to target immunogen sites;
6. The identification of universal or new immunogen targets of SARS-CoV-2.

We look forward to receiving your contributions.

Dr. Chang Li
Dr. Penghua Wang
Prof. Dr. Bin Zhou
Guest Editor



mdpi.com/si/117271

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com